As of September 30, 2024, the Company had approximately $32.4 million in cash and cash equivalents compared with $48.5 ...
Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 ...
Immutep (IMMP) announces positive data from investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA ... of anti-PD-1 and doublet chemotherapy ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...
Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback